Podcasts about objectives

This episode of the Becoming Centered Podcast presents four major parts to a residential treatment program's House Meetings (a regularly scheduled meeting of staff and clients).  Each part, (1) check-ins, (2) announcements, (3) group discussions / agenda items, and (4) wrap-up provides a forum for promoting resilience, self-regulation, social skills, and team-building. Regardless of the specific content of any single meeting, staff focus on four aspects of resilience, four aspects of self-regulation, and four aspects of "meeting behaviors" or social skills.  Resilience is promoted through encouraging the kids to experience, due to their participation in House Meeting, a sense of belonging, purpose, agency, and meaning.  Improved self-regulation is promoted through encouraging emotional sensitivity, through presenting evidence to support positive beliefs, through discussing values, and through giving the kids opportunities to practice their executive skills. The "meeting skills" of respectful listening, stating opinions appropriately, giving and receiving feedback, and negotiating and compromising are taught and encouraged through every part of the House Meeting. By using House Meetings to provide treatment aimed at improved resilience, self-regulation, and social skills the residential counseling staff will guide the kids through the forming, storming, and norming phases of team development to turn them into a high-performing team that provides each client with a transformative residential treatment experience. 

Sir Max Hastings describes specialized armored funnies that supported British landings on Sword Beach, noting that while technically successful, heavy traffic and Montgomery's overly ambitious objectives prevented the Allies from capturing Caen on D-Day. 121944 Sir Max Hastings describes specialized armored funnies that supported British landings on Sword Beach, noting that while technically successful, heavy traffic and Montgomery's overly ambitious objectives prevented the Allies from capturing Caen on D-Day. 121944 SWORD BEACH

In dieser Ask-Me-Anything-about-OKR-Episode des Murakamy Podcasts geht es um konkrete Spannungsfelder der OKR-Praxis: um den Unterschied zwischen Outcome und Output, um Tagesgeschäft versus Wandel und um Verantwortung in organisationaler Unschärfe. Wir diskutieren, warum „as measured by“ kein harmloser Shortcut, sondern ein Bruch in der OKR-Logik ist. Es geht darum, wie mit 80 Prozent Tagesgeschäft umzugehen ist, die Ressourcen binden, aber keine Verbesserung versprechen. Und wir fragen, was mit Zielen passiert, wenn sich Rollen, Aufbauorganisation und Verantwortlichkeiten permanent verändern. Die Folge macht deutlich, warum saubere Zielarbeit immer eine Führungsfrage ist – und weshalb OKRs dort scheitern, wo Entscheidungen vertagt oder delegiert werden.

Transitioning to competency-based education in nursing simulation education requires a systematic approach to curriculum assessment. Using the University's Online Simulation System, 2 experts selected American Association of Colleges of Nursing (AACN) behavioral performance indicators that best matched behavioral outcomes associated with simulation student roles in 5 scenarios. In this podcast and article, Dr. Anita Stephen describes the 3-phased approach they used to align cognitive simulation objectives to competencies identified in the AACN behavioral performance indicators. This approach can be used by faculty in other schools. 

Dante Lauretta explains how after a 2007 rejection he refined the science objectives, coining the name OSIRIS-REx, then assumed leadership after Mike Drake's passing and guided the team through a critical 2014 confirmation review to secure NASA approval.

Day 4 || 14th February 2026 || Objectives of the SKSG || 016 by CMFIONLINE

Work is noisy. Not just the hum of open-plan offices or the ping of endless emails, but the soul-sapping, productivity-killing corporate noise—the meetings that should have been emails, the politics that should have been resolved, and the reports that should have been binned. In this episode of A Job Done Well, Jimmy and James dissect the chaos of modern workplaces, where conflicting agendas, ego-driven leaders, and short-termism turn even the simplest tasks into a slog through quicksand.From the absurdity of "magnet ball" management (where everyone chases the same ball, achieving nothing) to the silent killer of organisational focus, they expose why noise thrives—and how you can fight back. Their advice? Be proactive, face into the problem, and for God's sake, stop blind-copying people on emails. With their usual mix of dry wit and hard-won wisdom, they arm you with tactics to cut through the clutter, protect your sanity, and maybe—just maybe—get your actual job done.Key Points:Noise is inevitable, but not unstoppable. It's the corporate ivy choking your productivity—meetings, emails, politics, and misaligned objectives.Ask: Does this make the boat go faster? If not, it's noise.Egos and silos fuel the chaos. Leaders broadcast; teams retreat. The result? A symphony of distraction.Data beats drama. Facts cut through opinion. If someone says “they always…”, ask: Who's ‘they'? What's ‘always'?Don't be part of the problem. Stop blind CC'ing the world, own your mistakes, and—above all—do something about it.Got a question - get in touch. Click here.

TOPICS: Iran Protests Trump Objectives Kyle Wagner Arrested Kamala Harris Coffee Talk with David Eon (LIVE WEEKDAY DAILY NEWS TALK) for Friday, February 6th, 2026.

In this episode of The Quality Hub, Chatting with ISO Experts, host Xavier Francis welcomes back Suzanne Weber-Smatko, Director of Consulting Services at Core Business Solutions, for a practical and engaging discussion on ISO 9001 and the critical importance of aligning strategic objectives with quality objectives. Together, they explore why quality management systems should support business strategy—not operate as a parallel compliance exercise—and where organizations often go wrong by treating quality as a cost center rather than a strategic tool. The conversation covers leadership ownership, cascading objectives from the top down, engaging employees at all levels, and using meaningful metrics, risk-based thinking, and management review to drive real business value. Whether you're part of a small business or a larger organization, this episode offers actionable insights on how to integrate quality into your strategy to improve performance, engagement, and results.   Helpful Resources: How is ISO 9001 Implemented?:  https://www.thecoresolution.com/how-is-iso-9001-implemented For All Things ISO 9001:2015: https://www.thecoresolution.com/iso-9001-2015 Contact us at 866.354.0300 or email us at info@thecoresolution.com A Plethora of Articles: https://www.thecoresolution.com/free-learning-resources ISO 9001 Consulting: https://www.thecoresolution.com/iso-consulting

Graham Richardson, CFO of Faraday Copper (TSX:FDY – OTCQX:CPPKF), joins me to provide a comprehensive #exploration overview of the key objectives and targets of the ongoing 40,000 meter Phase 4 drill program, at their 100% owned Copper Creek Project in Arizona. This drilling will be factoring into an updated copper Resource Estimate, and will be combined with other data-collection and metallurgical studies which are all feeding into more advanced project economics.   Half of this Phase 4 drill program will continue to be focused on defining, expanding, and testing new targets all around the American Eagle Area of the Project. Graham and I discuss the follow up plan for a number of key targets at the recently discovered Banjo Breccia and Winchester Breccia, Giuseppe, and Prada.  In addition, 10,000 meters will be allocated on true exploration by putting some holes into earlier-stage exploration targets at the Sunrise Trend and Bunker Hill area (which may indicate the presence of a new porphyry system).   Highlights from the first batch of drill holes from Phase 4:   Five drill holes in the American Eagle area intersected near-surface mineralization above open pit cutoff grade and further the potential for an open pit resource to be defined above the existing American Eagle underground resource.   Drill hole FCD-25-134 intersected several mineralized intervals for a combined 177 metres (“m”) greater than 0.30% copper, expanding the known extent of the Winchester breccia to within 100 m from surface. Copper intercepts include: 17.58 m at 0.44% copper from 109.42 m; 16.46 m at 0.57% copper from 184.54 m; and 45.25 m at 0.42% copper from 256.28 m.   North of the Banjo breccia, drill hole FCD-25-129 intersected 56.00 m at 0.41% copper from 160.00 m (approximately 100 m below surface), including 24.00 m at 0.64% from 164.00 m. The drill holes reported herein further increased confidence of the near-surface mineralization in the American Eagle area and geotechnical holes confirmed the rock competency is consistent with the current resource, and is suitable for efficient open pit mining.     About 10,000 meters of the Phase 4 campaign will be following up on results from Phase 3 that targeted near-surface supergene copper mineralization with the goal of better understanding the distribution of oxide mineralization. This near-surface oxide mineralization would be leachable and important in the early years of a development scenario of the Copper Creek Project.   In addition to expanding mineralization, testing new breccia targets, and infilling the American Eagle area in the upcoming Phase 4 drilling, there still will be some further definition holes drilled down into the deeper porphyry targets at the American Eagle and Keel deposits to better understand the geological controls, hydrology, and structural mineralization.   The company is well cashed up to complete all these work programs in 2026.  Graham highlights the strong roster of shareholders, including the Lundin Family and Murray Edwards, as well as a number of institutional investment firms.  We wrap up discussing the infrastructure advantages and positives of operating in Arizona as a jurisdiction.    If you have any questions for Graham regarding Faraday Copper, then please email them to me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Faraday Copper at the time of this recording, and may choose to buy or sell shares at any time.   Click here to view the latest news from Faraday Copper   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

"Get more leads" is NOT a marketing objective.If you've ever rushed through setting your marketing objectives just to get to the "real work," this episode is going to change everything.

Understanding how ransomware works is critical for anyone responsible for protecting their organization's data. In this episode of The Backup Wrap-up, we examine the five core objectives that drive nearly every ransomware attack - from initial access through the final ransom note delivery.I'm joined by my co-author Dr. Mike Saylor as we kick off what's going to be a comprehensive series on our new book, "Learning Ransomware Response and Recovery." We start at the beginning: how do these attackers even get in? Mike breaks down the role of initial access brokers (IABs) - the bad guys who specialize in harvesting and selling credentials. We talk about why email phishing remains the cheapest and most statistically reliable attack vector, even with all our defenses.From there, we walk through lateral movement and reconnaissance. Once attackers are inside your network, they're not sitting idle. They're mapping your environment, identifying your crown jewels, and figuring out where your backups live. The "phone home" phase establishes command and control, letting attackers coordinate their activities and receive instructions.We dig into data exfiltration and the rise of double extortion. It's not enough anymore to just encrypt your data - attackers are stealing it first, threatening to publish it even if you can restore from backups. Mike shares some fascinating details about how sophisticated ransomware can be, including variants that examine file headers rather than just extensions to find valuable targets.The encryption phase itself is resource-intensive, and Mike explains why you might actually notice your computer acting weird if you're paying attention. Your mouse hesitates, typing lags, the network slows down - these are all potential warning signs.Finally, we cover how ransom notes are delivered today. Spoiler: it's not the old-school desktop background takeover anymore. Modern ransomware drops text files in every folder it touches, making sure you can't miss the message.This episode sets the foundation for understanding how ransomware works, which is the first step in defending against it and recovering when prevention fails.

- Jonathan Coppess, University of Illinois  - Brad Stotler, Illinois Corn Growers Association  - KJ Johnson, IL Fertilizer and Chemical Association  ★ Support this podcast ★

Disclaimer: Money Makers has not had the opportunity to speak to the Chairman of Baillie Gifford Shin Nippon regarding the future of the investment trust, however it was deemed justified to publish this discussion on the ground of interest to shareholders with the proposal for a tender offer being put to a vote in mid-February. Money Makers remains neutral to the outcome for the trust. -- In this edition of the Money Makers Investment Trusts Podcast, Jonathan Davis, editor of the Investment Trusts Handbook and winner of the AIC Best Broadcast Journalist Award (2024 and 2025), is joined by Edward Cartwright, CEO of Arcus Investment Management, to discuss the proposal to manage the Baillie Gifford Shin Nippon Trust (BGS). This discussion was recorded on Tuesday 27 January 2026. *** OUT NOW: The 2026 Investment Trusts Handbook *** Available to order from Harriman House: https://harriman-house.com/authors/jonathan-davis/the-investment-trusts-handbook-2026/9781804094358 The Investment Trusts Handbook 2026 is the ninth edition of the highly regarded annual handbook for anyone interested in investment trusts – often referred to as the City's best-kept secret, or the connoisseur's choice among investment funds. It is expertly edited by well-known author and professional investor Jonathan Davis, founder and editor of the Money Makers newsletter and podcast. The Investment Trusts Handbook 2026 is an independent educational publication, available through bookshops and extensively online. With articles by 30 different authors, including analysts, fund managers and investment writers, plus more than 80 pages of detailed data and analysis, the latest edition is an indispensable companion for anyone looking to invest in the investment trust sector. *** Section Timestamps: 0:00:24 - Introduction 0:00:32 - The proposition to the board of Baillie Gifford Shin Nippon (BGS) 0:03:35 - The tender offer from BGS 0:09:52 - A short break 0:10:55 - Objectives at the upcoming tender offer meeting 0:14:13 - Getting the message out to retail shareholders 0:16:30 - The Japanese small cap market 0:20:46 - Close If you enjoy the weekly podcast, why not also try the Money Makers Circle? This is a membership scheme that offers listeners to the podcast an opportunity, in return for a modest monthly or annual subscription, to receive additional premium content, including interviews, performance data, links to third party research, market/portfolio reviews and regular comments from the editor. A subscription costs £12 a month or £120 for one year. As well as the usual features, the Circle currently features a profile of the Achilles Investment Company (AIC), with future profiles including Aberforth Geared Value & Income (AGVI) and Geiger Counter (GCL). Our new expanded weekly subscriber email includes a comprehensive summary of all the latest news plus the week's biggest share price, NAV and discount movements. Subscribe and you will never miss any important developments from the sector. For more information please visit https://money-makers.co/circle. Membership helps to cover the cost of producing the weekly investment trust podcast, which will continue to be free for the foreseeable future. We are very grateful for your continued support and the enthusiastic response to our more than 300 podcasts since launch. You can find more information, including relevant disclosures, at www.money-makers.co. Please note that this podcast is provided for educational purposes only and nothing you hear should be considered as investment advice. Our podcasts are also available on the Association of Investment Companies website, www.theaic.co.uk. Produced by Ben Gamblin - www.bgprofessional.co.uk

The OKR Illusion, Why Structure Without Direction Is Just NoiseOKRs (Objectives and Key Results) have gained significant traction over the past decade, especially after being widely adopted and championed by companies like Google. Originally developed at Intel, OKRs are a simple yet powerful framework for setting and tracking goals. At their core, OKRs are about defining what you want to achieve (Objectives) and how you'll measure progress (Key Results). While the concept is simple, the impact lies in how OKRs align teams, create focus, and connect everyday work to meaningful, measurable outcomes.How to connect with AgileDad:- [website] ⁠https://www.agiledad.com/⁠- [instagram] ⁠https://www.instagram.com/agile_coach/⁠- [facebook] ⁠https://www.facebook.com/RealAgileDad/⁠- [Linkedin] ⁠https://www.linkedin.com/in/leehenson/

Episode 15 is a different kind of New Year's Eve conversation—less “resolution energy,” more real life, real leadership, real presence.Jay Doran and Jenna Silverman sit down with Michael Allosso and Joseph Iredell during the 2025 Lollapalooza to unpack the theme:“Life is not a problem to be solved, but a reality to be experienced.”From the jump, it's personal—Mike Calhoun has officially tapped out after an all-day hosting marathon, and Jenna steps in to co-lead the room. What follows is a layered discussion about the words that shaped 2025 and the words driving 2026:Michael Allosso (2025): Seen & Heard — the ache of invisibility, and the power of making people feel visible.Michael (2026): Intensity — no more passive interactions; every moment becomes an event, with real stakes.Joseph Iredell: moves from Understanding into Dominance for 2026—less introspection, more execution, and refusing to “play defense” after momentum is built.Jenna: reflects on Faith in 2025 and anchors 2026 in Surrender—letting go of forced outcomes while staying disciplined about clarity, communication, and aligned action.The episode also hits a few Culture Matters gold veins: casting vs. hiring, why leaders misplace people into roles that drain them, and why “stakes” change everything—your tone, your preparation, your presence, and the way people remember you.They close by wrestling with a big question: How do you teach values in a way that's engaging—lived, not lectured?The answer keeps circling back to the same truth: values become real when they show up inside conversations, decisions, and the way we treat people when no one's watching.If you're heading into 2026 craving more presence, more purpose, and fewer forced outcomes—this one will land.

The conversation centers around the Transition to Organic Partnership Program (TOPP), a USDA initiative aimed at supporting farmers in transitioning to organic practices. Ben Bowell and Jessy Beckett Parr discuss the program's origins, goals, and the collaborative efforts of various organizations involved. They highlight the importance of technical assistance, mentorship, and community building in fostering a successful organic farming network. The discussion also touches on the program's impacts, future sustainability, and the significance of respect and collaboration in achieving a better world for agriculture.Takeaways:TOPP is a USDA initiative with a $100 million budget.The program aims to support farmers transitioning to organic practices.Collaboration among organizations is key to the program's success.Technical assistance includes one-on-one support and mentorship.The program has reached thousands through various educational events.Farmers are compensated for mentoring new organic farmers.The program is designed to be community-based and regionally tailored.Future funding and sustainability are ongoing concerns for the program.The program aims to increase domestic organic production to meet consumer demand.The national partners are Organic Farmers Association, Trade Association, and Arizona State University Swette Center for Sustainable Food Systems.The Regional Leads are Oregon Tilth, CCOD, OCIA, MOSA, Florida Organic Growers, and PCO.Modern Species developed their 2025 Impact Report which helped them secure the remainder of their grant after the government funding freeze.Sound bites:“If there's already the organic demand, we just need to meet the supply domestically.”“People in the United States who are inside of larger agricultural corporations, food-based corporations, see the disconnect and the need to invest resources in domestic supply and production.”“We all cooperatively wrote the organic standards together, along with other movement aligned groups in the 90s.”“One of the emergent themes for us of this work has been how important the network itself is and how keeping people in collaboration across organizations and state boundaries supports all of our success.”“I love hearing the stories of the farmer to farmer sharing. It's really powerful.”“I really feel like a better world looks like a world that's full of respect, for the people, for the planet and its delicate balance of biology and ecology.”"It's about continuous improvement."Links:Transition to Organic Partnership Program - https://www.organictransition.org/Impact Report for Transition to Organic Partnership Program - https://www.organictransition.org/impact-report/Ben Bowell on LinkedIn - https://www.linkedin.com/in/ben-bowell-85901a1b3/Jessy Becket Parr on LinkedIn - https://www.linkedin.com/in/jessy-beckett-parr-a5a681185/…Brands for a Better World Episode Archive - http://brandsforabetterworld.com/Brands for a Better World on LinkedIn - https://www.linkedin.com/company/brand-for-a-better-world/Modern Species - https://modernspecies.com/Modern Species on LinkedIn - https://www.linkedin.com/company/modern-species/Gage Mitchell on LinkedIn - https://www.linkedin.com/in/gagemitchell/…Print Magazine Design Podcasts - https://www.printmag.com/categories/printcast/…Heritage Radio Network - https://heritageradionetwork.org/Heritage Radio Network on LinkedIn - https://www.linkedin.com/company/heritage-radio-network/posts/Heritage Radio Network on Facebook - https://www.facebook.com/HeritageRadioNetworkHeritage Radio Network on X - https://x.com/Heritage_RadioHeritage Radio Network on Instagram - https://www.instagram.com/heritage_radio/Heritage Radio Network on Youtube - https://www.youtube.com/@heritage_radioChapters:03:00 Introduction to the Transition to Organic Partnership Program04:33 Understanding the Transition to Organic Partnership Program07:57 The Role of Partnerships in Organic Transition09:07 Regional Partners and Their Selection Process11:31 Goals and Objectives of the Transition to Organic Partnership Program15:20 Highlights and Accomplishments of the Program20:14 The Importance of Collaboration and Community23:37 Managing a Successful Collaborative Program26:54 Getting Involved in the Program29:13 Who is the Program For?31:06 Free Resources and Support for Farmers32:16 Future Plans for the Program35:00 Funding Opportunities and Strategies37:36 Advice for Collective Action and CollaborationSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Call Your Hits, Phil interviews Nick and Alex, co-founders of Zone 37, an innovative Airsoft live action role-playing event in California. They discuss their journey from traditional Airsoft experiences to creating a unique immersive environment that emphasizes player agency, storytelling, and community involvement. The conversation covers the challenges of event coordination, the importance of feedback, and the future growth of Zone 37, including plans for larger events and maintaining the immersive atmosphere that players have come to love.Chapters00:00 Introduction to Zone 37 and Its Founders02:57 The Evolution of Airsoft Experiences05:52 The Birth of Zone 37: Concept and Development09:11 Testing Ideas and Community Engagement11:51 The World of Zone 37: Factions and Storytelling14:59 Welcoming New Players into the Zone18:01 Player Agency and Event Dynamics20:56 Factions and Player Roles23:53 Objectives and Player Motivation26:57 Player Interactions and Community Dynamics29:57 Creating Immersion in the Zone35:38 Creating an Immersive Community Experience39:01 Building Atmosphere and Creepiness in Gameplay44:29 Balancing Tension and Player Experience49:31 Adapting to Player Feedback and Event Dynamics54:00 Defining the Zone 37 Experience01:00:16 Future Aspirations and Business Strategies--- If you're looking to support the channel, check out our merch store here: https://stormriders.threadless.com/ And join our discord by following this link: https://discord.gg/ZdaftDDYaZ

 Jeff Wieland, host of the WB Download podcast, discussed various updates and goals for Wieland Builders in 2026. The company will discuss these and additional goals at an upcoming scheduled retreat. The company aims to achieve $12 million in revenue, focusing on building fewer high-value custom homes. They plan to implement a mutual success agreement with customers, emphasizing accountability and clear expectations. Wieland Builders will use Builder Trend for better project management and customer communication. They also intend to improve trade evaluations, enhance customer service, and continue to celebrate client milestones. Email Jeff your comments, questions, and topic requests, or be a guest on The WB Download.Email: WBDOWNLOAD@wielandbuilders.comSee Wieland Builders custom home gallery  www.wielandbuilders.comReceive inspiration monthly in our monthly newsletter See podcast behind the scenes photosFollow us on Facebook, Instagram, YouTube, Houzz or Pinterest 

We dig into why traffic is fragmenting, why single-channel expertise won't cut it, and how expert generalists, stronger offers, and brand strategy are now the true growth levers. We share a practical path from productized “done-for-you” to higher-margin “done-with-you,” plus frameworks for attribution, remote team performance, and human-in-the-loop AI.• AI-driven traffic shifts and platform changes• Generalists with deep skills as the new edge• Offers, positioning, and CRO over channel tricks• Human-in-the-loop standards to avoid AI slop• Done-with-you consulting to expand TAM and margin• Retainers, value pricing, and capacity planning• Attribution redesign and qualification signals• Objectives, metrics, KPIs, and NPS for retentionGuest Contact Information: Website: agencyacquisitions.ioLinkedIn: linkedin.com/in/nickavariaTwitter/X: x.com/Nick_AvariaYouTube: youtube.com/@AgencyAcquisitionsInstagram: instagram.com/nick_avariaMore from EWR and Matthew:Leave us a review wherever you listen: Spotify, Apple Podcasts, or Amazon PodcastFree SEO Consultation: www.ewrdigital.com/discovery-callWith over 5 million downloads, The Best SEO Podcast has been the go-to show for digital marketers, business owners, and entrepreneurs wanting real-world strategies to grow online. Now, host Matthew Bertram — creator of LLM Visibility™ and the LLM Visibility Stack™, and Lead Strategist at EWR Digital — takes the conversation beyond traditional SEO into the AI era of discoverability. Each week, Matthew dives into the tactics, frameworks, and insights that matter most in a world where search engines, large language models, and answer engines are reshaping how people find, trust, and choose businesses. From SEO and AI-driven marketing to executive-level growth strategy, you'll hear expert interviews, deep-dive discussions, and actionable strategies to help you stay ahead of the curve. Find more episodes here: youtube.com/@BestSEOPodcastbestseopodcast.combestseopodcast.buzzsprout.comFollow us on:Facebook: @bestseopodcastInstagram: @thebestseopodcastTiktok: @bestseopodcastLinkedIn: @bestseopodcastConnect With Matthew Bertram: Website: www.matthewbertram.comInstagram: @matt_bertram_liveLinkedIn: @mattbertramlivePowered by: ewrdigital.comSupport the show

Why do we wait for Mondays to change our lives? Today, we deconstruct the "Fresh Start Effect." We move beyond flimsy resolutions and learn how to set "Objectives and Key Results" (OKRs) just like Silicon Valley tech giants. Plus, we master the "Future Perfect" tense to visualize success and sound more authoritative in meetings. To unlock full access to all our episodes, become a premium subscriber on Apple Podcasts or Patreon. And don't forget to visit englishpluspodcast.com for more content and learning.

FAN MAIL--We would love YOUR feedback--Send us a Text MessageA nighttime city goes dark, rotors whisper over rooftops, and a regime built on crime loses its center of gravity. That image anchors a frank, fast-moving breakdown of Operation Absolute Resolve—the surgical extraction that removed Nicolás Maduro without a single U.S. casualty or aircraft loss. We open with first principles from Liberty and Tyranny, asking what prudence requires when unalienable rights collide with the limits of American responsibility, then test those principles against a real-world mission that felt more like law enforcement than nation building.I walk through the skeptical reflex shaped by Iraq and Afghanistan and explain why the facts on the ground shifted my view. Maduro's Venezuela wasn't acting like a sovereign state; it was operating as a transnational cartel hub funneling cocaine and fentanyl into American streets while inviting Russia, China, and Iran into our hemisphere. That changes the moral math. We draw the line from Noriega's Panama to Caracas, show how sovereignty erodes when a ruler weaponizes the state for organized crime, and clarify why a narrow objective—remove the cartel boss in a presidential sash—served both justice and deterrence.From there, we unpack the mission profile: more than 150 aircraft, coordinated cyber effects, lights out over Caracas, target hit at 2:01 a.m., and a clean exfil. No occupation. No open-ended promises. Just a defined aim met with precision and restraint. The takeaway is not triumphalism but discipline: peace through strength means clarity of purpose, proportional means, and a hard stop once the job is done. We close with practical guardrails to prevent mission creep and a look ahead to part two on Venezuela's next chapter and regional stability. If this analysis resonates, follow the show, share it with a friend who cares about strategy and ethics, and leave a review to help more listeners find the conversation.Key Points from the Episode:We weigh the moral and strategic case for removing Nicolás Maduro through a surgical extraction that avoided quagmire while targeting a criminal enterprise masquerading as a state. We connect prudence, sovereignty, and the Monroe Doctrine to a Reagan-style peace through strength.• Levin's framework on rights, limits, and prudence• Skepticism after Iraq and Afghanistan• Operation Absolute Resolve planning and execution• Maduro as narco-terrorist and illegitimate ruler• Noriega precedent and sovereignty boundaries• Monroe Doctrine and great-power presence• Objectives achieved without occupation• Guardrails to prevent mission creepJoin us later in the week at TeammojoAcademy.com for part 2 Be sure to check out our show page at teammojoacademy.com, where we have everything we discussed in this podcast as well as other great resourcesOther resources: Want to leave a review? Click here, and if we earned a five-star review from you **high five and knuckle bumps**, we appreciate it greatly!

The Lever reports that Trump's removal of Nicolás Maduro could tilt international court proceedings and provide a windfall to corporate plaintiffs.

We're always talking about how to create strategic plans and then execute them with intention for immediate action and measurement. As we like to do on this show, we bring forth many different approaches and ways of thinking, because we know not every tool is a one-size-fits-all. Today, that focus is on the OKR framework aka Objectives & Key Results. We wanted you to learn from an expert who knows OKRs better than anyone, so we welcomed on Philipp Schett. He's the Founder of Wave Nine, the #1 OKR consulting firm. You'll also love their free OKR Crash Course. For more about ForthRight Business by ForthRight People or for 1:1 consultation, check us out at ForthRight-Business.com And as always, if you need Strategic Counsel, don't hesitate to reach out to us at: ForthRight-People.com FACEBOOK https://www.facebook.com/forthrightpeople.marketingagency INSTAGRAM https://www.instagram.com/forthrightpeople/ LINKEDIN https://www.linkedin.com/company/forthright-people/ RESOURCES https://www.forthright-people.com/resources VIRTUAL CONSULTANCY https://www.forthright-people.com/shop

- Jonathan Coppess, University of Illinois  - Brad Stotler, Illinois Corn Growers Association  - KJ Johnson, IL Fertilizer and Chemical Association  From the Land Grant University in Urbana-Champaign, Illinois this is a special edition of the Closing Market Report. Presentations from the 2025 Farm Assets Conference; Ag Policy Objectives and Prospects. I'm University of Illinois Extension's Todd Gleason.Up next a critical discussion on the evolving landscape of agricultural policy and markets. This panel features KJ Johnson of the Illinois Fertilizer and Chemical Association, Brad Stotler from the Illinois Corn Growers Association, and Jonathan Coppess of the University of Illinois.Together, we'll dive into the pressing issues facing farmers today, including: - Market Shifts: The transition from ethanol toward new domestic marketplaces for corn.   - Political Climate: The impact of record-breaking congressional retirements and shifting partisan dynamics in Washington and Springfield.   - Trade and Tariffs: The rising concern over fertilizer and chemical costs driven by international trade tensions.   - The Farm Bill: A deep look at the controversial decoupling of food assistance programs from traditional farm subsidies.30:11 running time  ★ Support this podcast ★

As a new year approaches, God invites us to plan, not with worry, but with purpose. Planning reflects faith, wisdom, and trust in His promises. Count the cost, write the vision, and step forward with hope. God delights in purposeful beginnings.This devotional was aired on Radio HCI Today via the WeLove Radio App.

Tait Duryea and Ryan Gibson close out 2025 by pulling back the curtain on how high performers actually plan, execute, and stay intentional across money, business, and family life. From Spartan's acquisition pace and Turbine's investor roadmap to family board meetings, goal frameworks, and habit formation, this episode offers a grounded look at what it takes to build momentum year after year. If you want clarity instead of drift and action instead of resolutions, this conversation sets the tone for a focused, intentional 2026. Do not just listen. Decide who you are becoming and move.Show notes:(0:00) Intro(2:27) Family board meetings explained(4:32) Objectives and key results framework(6:29) Spartan's 2025 growth numbers(9:29) Turning big ideas into action(12:21) Why most people never get clear(15:49) Day one Vs. One day mindset(18:40) Stability, mentorship, and leadership(21:02) Why 2026 looks like opportunity(23:36) OutroIf you're interested in participating, the latest institutional-quality self-storage portfolio is available for investment now at: https://turbinecap.investnext.com/portal/offerings/8449/houston-storage/ — You've found the number one resource for financial education for aviators! Please consider leaving a rating and sharing this podcast with your colleagues in the aviation community, as it can serve as a valuable resource for all those involved in the industry.Remember to subscribe for more insights at PassiveIncomePilots.com! https://passiveincomepilots.com/ Join our growing community on Facebook: https://www.facebook.com/groups/passivepilotsCheck us out on Instagram @PassiveIncomePilots: https://www.instagram.com/passiveincomepilots/Follow us on X @IncomePilots: https://twitter.com/IncomePilotsGet our updates on LinkedIn: https://www.linkedin.com/company/passive-income-pilots/Do you have questions or want to discuss this episode? Contact us at ask@passiveincomepilots.com See you on the next one!*Legal Disclaimer*The content of this podcast is provided solely for educational and informational purposes. The views and opinions expressed are those of the hosts, Tait Duryea and Ryan Gibson, and do not reflect those of any organization they are associated with, including Turbine Capital or Spartan Investment Group. The opinions of our guests are their own and should not be construed as financial advice. This podcast does not offer tax, legal, or investment advice. Listeners are advised to consult with their own legal or financial counsel and to conduct their own due diligence before making any financial decisions.

Liubov Velychko is a Ukrainian investigative journalist with over 15 years of experience uncovering corruption, crime, and human rights violations. She Specializes in exposing disinformation campaigns, and has conducted numerous investigations into Russian propaganda, revealing the networks behind its spread and dismantling the information operations orchestrated by Russian intelligence agencies.----------LINKS:https://www.linkedin.com/in/v-press/ https://www.rusi.org/people/velychkohttps://x.com/VelychkoLiubovhttps://www.occrp.org/en/people/lyubov-velychkohttps://mind.ua/en/author/1158-liubov-velychko----------Silicon Curtain is a part of the Christmas Tree Trucks 2025 campaign - an ambitious fundraiser led by a group of our wonderful team of information warriors raising 110,000 EUR for the Ukrainian army. https://car4ukraine.com/campaigns/christmas-tree-trucks-2025-silicon-curtainThe Goal of the Campaign for the Silicon Curtain community:- 1 armoured battle-ready pickupWe are sourcing all vehicles around 2010-2017 or newer, mainly Toyota Hilux or Mitsubishi L200, with low mileage and fully serviced. These are some of the greatest and the most reliable pickups possible to be on the frontline in Ukraine. Who will receive the vehicles?https://car4ukraine.com/campaigns/christmas-tree-trucks-2025-silicon-curtain- The 38th Marine Brigade, who alone held Krynki for 124 days, receiving the Military Cross of Honour.- The 1027th Anti-aircraft and artillery regiment. Honoured by NATO as Defender of the Year 2024 and recipient of the Military Cross of Honour.- 104th Separate Brigade, Infantry, who alone held Kherson for 100 days, establishing conditions for the liberation of the city.- 93rd Brigade "Kholodnyi Yar", Black Raven Unmanned Systems Battalion ----------SUPPORT THE CHANNEL:https://www.buymeacoffee.com/siliconcurtainhttps://www.patreon.com/siliconcurtain----------TRUSTED CHARITIES ON THE GROUND:Save Ukrainehttps://www.saveukraineua.org/Superhumans - Hospital for war traumashttps://superhumans.com/en/UNBROKEN - Treatment. Prosthesis. Rehabilitation for Ukrainians in Ukrainehttps://unbroken.org.ua/Come Back Alivehttps://savelife.in.ua/en/Chefs For Ukraine - World Central Kitchenhttps://wck.org/relief/activation-chefs-for-ukraineUNITED24 - An initiative of President Zelenskyyhttps://u24.gov.ua/Serhiy Prytula Charity Foundationhttps://prytulafoundation.orgNGO “Herojam Slava”https://heroiamslava.org/kharpp - Reconstruction project supporting communities in Kharkiv and Przemyślhttps://kharpp.com/NOR DOG Animal Rescuehttps://www.nor-dog.org/home/----------

This week marks our last WB Download podcast episode of the year! Jeff Wieland wraps up 2025 with a recap of the incredible guests he's had the pleasure of interviewing throughout the year.We're incredibly thankful for our listeners, guests, and the WB Download team who continue to make this podcast such a success. Your support means everything to us.Here's to continued conversations, great stories, and growing our podcast community in 2026!#50 Kathy Wyenandt, Client and Friend#51Crosby & Robi Simms- Simms Development#52 Ferguson, Sarah Muri and Mark Waflart#53 SiteWorx, Matt Smith#54 Jeff 2025 Goals and Objectives#55 Florida Tile - Kelly Schnelle#56 Ryan Murphy Insurance#57 Sue Wieland -Mothers Day#58 California Closets - Leah Eggert & Krista Heinrich #59 Adam Hehlke, Built QC#60 Gordian Design & Construction, Johnny Lohr#61 Caroline on Design, Carrie Baker#62 Recognizing & Working With Tough Clients#63 Payton's Lemonade Stand, Payton & Jess Obert#64 KBR - Pam Carr#65 Simplify By Design, Danielle Boerger#66 Everything Homearama, Favorite Rooms & Luxury Designs#67 Andy Korb, Stockyards Packing#68 Brian Lapthorn, Client and Mental Health Advocate#69 Tanner Konrady, Konrady & Son#70 Don Weiler, Bailey Weiler Design Build#71 Then and Now Wieland BuildersEmail Jeff your comments, questions, and topic requests, or be a guest on The WB Download.Email: WBDOWNLOAD@wielandbuilders.comSee Wieland Builders custom home gallery  www.wielandbuilders.comReceive inspiration monthly in our monthly newsletter See podcast behind the scenes photosFollow us on Facebook, Instagram, YouTube, Houzz or Pinterest

This week, the team breaks down what recent platform moves signal for operators heading into 2026 - starting with Shopify's Winter Editions and the growing role of Sidekick inside the Shopify ecosystem. They discuss how tools like Sidekick are democratizing data access, reducing operational friction, and changing how lean growth teams analyze performance, build reports, and take action inside the admin.From there, the conversation shifts to BFCM performance and incrementality, with the hosts unpacking what they learned from scaling spend in steps during peak periods. They discuss where incremental gains showed up, where marginal returns began to flatten, and why short testing windows can still offer directional insight even when results are noisy.The team then reacts to and unpacks a tweet about Amazon bidding more aggressively on brand terms, using it as a jumping-off point to explore demand capture during promo periods, brand search strategy, and how branded demand is distributed across Amazon and DTC during high-intent moments.Throughout the episode, a key theme emerges: how operators should interpret signals from major platforms and translate them into proactive strategy rather than reactive tactics. The episode wraps with a candid conversation on 2026 planning, including examples like Connor Rolain's pyramid-style goal-setting framework, org design considerations, and how growth leaders can balance short-term execution with long-term thinking.If you have a question for the MOperators Hotline, click the link to be in with a chance of it being discussed on the show: https://forms.gle/1W7nKoNK5Zakm1Xv6Chapters:00:00:00 – Shopify Winter Editions and the Rise of Sidekick00:06:46 – Data Democratization and AI Inside Shopify00:14:34 – Shopify Collective and Cross-Brand Merchandising00:19:03 – Black Friday Scaling Tests and Marginal ROAS00:27:27 – Brand Search Incrementality and Paid Search Myths00:32:14 – Amazon Brand Bidding and the “Amazon Tax”00:36:39 – What CMOs Must Lock Before Year-End Planning00:41:22 – Hiring Plans, Budgets, and 2026 Readiness00:46:21 – Managing Multiple Timelines Across Growth Teams00:49:38 – Strategic Filters, Objectives, and Goal-Setting FrameworksPowered by:Motion.⁠⁠⁠https://motionapp.com/pricing?utm_source=marketing-operators-podcast&utm_medium=paidsponsor&utm_campaign=march-2024-ad-reads⁠⁠⁠https://motionapp.com/creative-trendsPrescient AI.⁠⁠⁠https://www.prescientai.com/operatorsRichpanel.⁠⁠⁠https://www.richpanel.com/?utm_source=MO&utm_medium=podcast&utm_campaign=ytdescAftersell.https://www.aftersell.com/operatorsRivo.https://www.rivo.io/operatorsHaus.http://Haus.io/operatorsSubscribe to the 9 Operators Podcast here: https://www.youtube.com/@Operators9Subscribe to the Finance Operators Podcast here: https://www.youtube.com/@FinanceOperatorsFOPSSign up to the 9 Operators newsletter here: https://9operators.com/

PESTO Trial Results: What Stroke Survivors Need to Know About Perispinal Etanercept If you've spent any time in stroke recovery communities, you've probably seen the same pattern: a treatment gets talked about with real intensity, people share personal stories that pull you in, and suddenly you're left trying to sort hope from hype from “maybe.” When the decision also involves significant cost, that uncertainty can feel even heavier. That's exactly why I recorded this episode: to help stroke survivors and their families understand the PESTO trial results in plain language without drama, without attacks, and without jumping to conclusions. In this interview, Professor Vincent Thijs explains what the PESTO trial set out to test, why it was designed the way it was, and what the results can (and can't) tell us about perispinal etanercept in stroke recovery. The real problem: not “hope vs skepticism”… it's confusion If you're a stroke survivor, you're already doing something heroic: you're living inside a recovery journey that demands patience, grit, and constant adjustment. The challenge isn't that you “don't want to believe” in something. The challenge is that it's genuinely hard to make an informed decision when: People report different outcomes Online conversations become polarised fast Scientific studies use unfamiliar language The same treatment can be described in completely different ways depending on who you're listening to My goal here isn't to tell you what to do. It's to help you think clearly, ask better questions, and understand what the best available evidence from this trial actually tested. What the PESTO trial was trying to investigate (in simple terms) Professor Thijs explains that the PESTO trial was designed in response to strong community interest. Stroke survivors wanted to know whether the way perispinal etanercept is currently administered in some settings could be demonstrated to work under the standards used for medicines to become widely accepted as part of routine care. So the researchers designed a randomized, placebo-controlled clinical trial. In this type of study: A computer assigns participants to either the treatment or a placebo Participants and clinicians are kept “blinded” (they don't know who got what) Outcomes are measured in a consistent way at set time points In the PESTO trial, the focus was on stroke survivors with moderate to severe disability and reduced quality of life. The primary question was straightforward: Does quality of life improve after one or two injections compared with placebo, over the measured timeframe? Why this study looked at quality of life (not one symptom) One key detail Professor Thijs highlights is the design choice: the trial didn't only target one issue, like pain or walking. It aimed to be more “pragmatic,” reflecting how treatment is used in real-world settings where people seek help for different post-stroke challenges (mobility, fatigue, speech, cognition, pain, and more). That means the main outcome wasn't “Did walking speed improve?” or “Did pain reduce?” It was broader: Quality of life at 28 days And again after the second injection timeframe (56 days total) This matters because your results can look different depending on what you measure. A trial targeting one symptom might see a signal that a broad quality-of-life measure doesn't detect (and vice versa). What the PESTO trial results found In Professor Thijs' words, the trial did not show a difference in quality of life between the treatment and placebo groups at the measured time points: No clear quality-of-life improvement at 28 days No clear improvement after two injections at 56 days That's the central outcome. But there's another finding that grabbed my attention—and it's one many listeners will find surprising. Quote block (mid-article): “We saw that 58% of the people also had that improvement [with placebo] and 53% had it with etanercept… our initial guess was very wrong.” — Professor Vincent Thijs The “placebo signal” and why it matters A strong placebo response doesn't mean “it was all in their heads.” It means that in a blinded clinical trial, people can improve for multiple reasons that aren't specific to the drug itself, such as: Expectation and hope Natural fluctuations in symptoms The impact of being monitored and supported Regression to the mean (symptoms often move toward average over time) The structure and attention that come with trial participation Professor Thijs describes how, during the blinded phase, participants reported improvements in a variety of areas (like sensation, vision, speech). The crucial point is: the team didn't know who had a placebo or an active treatment at the time, which is exactly why blinding exists. For you, the listener, this is a reminder of something empowering: Personal stories can be real and meaningful—and still not answer the question of efficacy on their own. “Am I a candidate?” The trial's honest answer: we don't know how to predict it (yet) One of the most important parts of this conversation is the desire to identify who might benefit most. Professor Thijs explains that the team looked at subgroups (for example: age, sex, severity, diabetes, time since stroke). In this trial, they didn't find a clear subgroup where the treatment stood out as reliably beneficial compared with placebo. He also adds an important caveat: subgroup analysis is difficult, especially in trials that aren't extremely large. So the absence of a clear “responder profile” here doesn't automatically prove none exists—it means this trial didn't reveal one. What this episode is (and isn't) saying Let's keep this grounded and fair. This interview is not about attacking any person, provider, or clinic. It's not about shaming stroke survivors who tried something. It's not even about telling you that you should or shouldn't pursue a treatment. It is about this: Understanding what the PESTO trial tested Understanding what the results showed within their timeframe Knowing the limits of what the trial can conclude Using evidence to reduce confusion before making big decisions A simple “clarity plan” before you decide anything big If you're considering any high-stakes treatment decision, here's a neutral, practical way to move forward: 1) Ask: “What outcome matters most for me?” Is it pain? walking? fatigue? speech? cognition? daily function? quality of life? A treatment might be studied for one outcome and discussed online for another. 2) Ask: “What does the best evidence say—specifically?” Not “Does it work?” in general, but: In what population? Using what method? At what dose? Over what timeframe? Compared with what? 3) Ask: “What are my options and trade-offs?” Talk with a qualified healthcare professional who understands your medical history, risk factors, and rehab plan. Ask about: Potential risks and side effects Opportunity cost (what else could you do with the same time, money, and energy?) Evidence-based rehab and supports that match your goals Listen to the full interview If you want the clearest explanation of the PESTO trial results—from the lead researcher himself—listen to the full episode with Professor Vincent Thijs. And if you'd like to support the podcast (and help keep these conversations going for stroke survivors who need hope and clarity): Bill's book: recoveryafterstroke.com/book Patreon: patreon.com/recoveryafterstroke Medical disclaimer This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs Confused about perispinal etanercept after stroke? Prof Vincent Thijs explains the PESTO trial results clearly, calmly, and evidence-first. More About Perispinal Etanercept: Etanercept Stroke Recovery: Wesley Ray's Relentless Comeback Dwayne Semple's Remarkable Stroke Journey and Perispinal Etanercept Etanercept for Stroke Recovery – Andrew Stopps Support The Recovery After Stroke Podcast on Patreon Highlights: 00:00 Introduction and Overview of the PESTO Trial 04:19 Design and Objectives of the PESTO Trial 11:23 Recruitment and Methodology of the Trial 18:31  PESTO Trial Results and Findings 24:28 Implications and Future Directions for Research 32:15 Conclusions and Final Thoughts Transcript: Introduction: PESTO Trial Results Bill Gasiamis (00:00) Hello and welcome back to Recovery After Stroke. Before we get started, a quick thank you to my Patreon supporters. Your support helps cover the hosting costs after more than 10 years of me doing this show solo. And it helps me keep creating episodes for stroke survivors who need hope and practical guidance. And thank you as well to everyone who comments on YouTube, leaves reviews on Spotify and Apple podcasts. buys the book and even to those of you who don’t skip the ads. Every bit of that supports keep this podcast going. Now today’s episode is about the PESTO trial results and I’m interviewing Professor Vincent Theis. If you’ve ever felt confused by the conversation online about perisponal antenna sept, some people sharing positive experiences while others are feeling disappointed and plenty of strong opinions in between, this episode is designed to bring clarity. We talk about what the PESTO trial set out to test, how the study was designed, what it found within the measured timeframes and what the results can and can’t tell us. Just a quick note, this conversation is educational and not medical advice. Always speak with a qualified health professional about your situation. All right, let’s get into it. Professor Vincent Dase, welcome to the podcast. Vincent Thijs (01:24) Thank you for having me, Bill. Bill Gasiamis (01:26) I’m really looking forward to this conversation. Atenosept is one of the most hotly discussed topics in stroke recovery. And there’s a lot of misconceptions about whether or not it is or is not efficacious. And while there’s a lot of anecdotal evidence where some people have had positive outcomes from injections, there’s also a lot of people’s feedback, which is very negative about their experience with the Etanercept injections and the lack of results. So today, the reason I reached out is because I wanted to get to the bottom of the findings of the PESTO trial. And I’m hoping that you can shed some light on that. The first question basically is, can you start by explaining in simple terms what it was that the PESTO trial set out to investigate? Vincent Thijs (02:22) All right. The PESTO trial was in response to community members, stroke survivors, wanting to find out whether the current practice of administering Etanercept has done in the U.S. in private practice. In Denmark, I hear there are some sites that provide this treatment. Whether the treatment and genders can be actually proven according to the standards that we use in the pharmaceutical industry to get it to become accepted as a standard of care treatment. For that, you need to do what we call a randomized controlled clinical trial, preferably two that show evidence that treatment does what it’s set out to do. And that’s why with this background and the community pressuring the minister several years ago, Mr. Hunt at the time, to fund a trial that would help answer that question. Design and Objectives of the PESTO Trial There was a call was set out to do this trial and several groups in Australia applied and then an independent committee decided to award the trial to the PESTO study group. And then we tried to design this trial to give an answer. So it’s mostly about people that have moderate to severe disability after their stroke that have reduced quality of life. And We wanted to know, does their quality of life improve when Etanercept is administered? And we wanted to test whether one or two injections were needed. Because that’s what we heard from stroke survivors that from Australia and internationally that went over to the US. Well, this is how it’s done. You get one or two injections and there was a paper that had shown big effects with one injection. So that was the primary endpoint, but then we also looked at whether two injections could help. And when you design a trial, you have to make a decision, will we focus on people with. pain after stroke, or will we look at people who have mobility issues or speech issues or cognitive issues? And we saw that current clinical practice actually was people with various impairments after stroke were accepted and received the treatment. And what would have been the advantage of doing say only mobility or only pain? Well, you can then look at the outcome of pain or mobility, does it improve? Or is your cognition improved? But because we wanted to be pragmatic and we know that recruitment in clinical trials needs to reflect how is current practice. So we thought let’s put in all the people with moderate to severe disability, whatever their impairment after stroke and reduce quality of life. And then we looked at quality of life as an outcome rather than an individual impairment. And so what we did then was to use the randomized technique and where it’s left up to the computer to decide what treatment a person will receive, the active Etanercept or a similar looking placebo, and then look at 28 days and we had to make a decision what makes sense 28 days, what is practical. to see whether that injection then had improved quality of life. And then we did another injection again with a placebo or the active drug. And then after 28 days again, we looked again whether that had made a difference. So we have people that had received two times the placebo, one time the placebo, and one active injection. And then we have people that had received two active injections. And then we were able to compare those and see whether they had made bigger improvements if you receive two injections versus one or zero. Unfortunately, we couldn’t show a difference in quality of life at 28 days. And we also couldn’t show an improvement at 56 days after people had two injections. But that was in a nutshell how we designed and the background of the study. Bill Gasiamis (07:25) So the main difference then between the Griffith University study and your particular study was that they did go after a specific improvement in one area, I believe. it in? Okay. So although those guys went after pain, you guys went after just a general improvement in quality of life after the injection and your stroke survivors. Vincent Thijs (07:39) Mostly, think. Bill Gasiamis (07:54) would have been as far as 15 years post stroke. Is that right? Vincent Thijs (07:59) Yes, correct. We wanted to have people early after stroke between one and five years, and then also between people five to 15 years after stroke. That was also for practical reasons. Once you start trial, you see how good recruitment is, how many people want to participate in the study. And we saw that if we went to up to five years. Recruitment was relatively slow. So we added this additional group of people later on after their stroke. that because many people, I’m five years, I’m six years after stroke. Why can’t I get the treatment? And you know, so we also wanted to expand the pool. And that’s also what happens in clinical practice. Current clinical practice, I don’t think the sites and the US and they would refuse the patient six years or so. We just wanted to reflect the people that we see on the website going for this treatment. Bill Gasiamis (09:01) Yeah, yeah. And then the difference between the Griffith trial and your trial as well was the actual dosage of Etanercept the amount that was in the injection. I do believe that your trial was a 25 milligram injection. And I believe that the Griffith University trial was 25 milligram. injection to 50 milligram injection. Vincent Thijs (09:34) Yeah, we just based on what people told us they received when they went to the clinic, also the other sites and then also 35 milligram was chosen because that’s in the patent for the street. Bill Gasiamis (09:49) Okay, I see. So you’re trying to as much as possible mimic what was happening out there in in the private practice Vincent Thijs (10:00) We wanted to answer the question, is current clinical practice, is that beneficial? And that’s what sort of what the call was to do a clinical trial in current clinical practice. You can, you have to make decisions, right? And I think this was the most relevant for a stroke survivor. Bill Gasiamis (10:17) Now that’s really interesting that stroke survivors were able to twist the arm of a minister to get the funding to begin that process of the trial. How long ago did this actually start? Vincent Thijs (10:28) I think it was 2016, 2017 or so. So it takes a while to get the minister and then I think that the trial started in 2019. took a while to complete as well. Bill Gasiamis (10:43) Right understood. Okay So then you recruit people they come along and they go through the trial through the particular trial How does that work on the day do they turn up are they admitted? We’ll be back with more of professor face explanation in just a moment But I want to pause here because if you’ve ever felt stuck between hope and uncertainty, you’re not alone When you’re recovering from stroke, you’re constantly making decisions and some decisions feel high stakes, especially when confronting information that’s conflicting. Recruitment and Methodology of the Trial In the second half of this conversation, we get into the parts that really help you think clearly. What the trial results do and don’t mean, and why placebo responses matter in blinded research, and how to frame smarter questions before you commit time, money, or energy to any path. If you want to support the podcast and keep these episodes coming, You can grab my book at recoveryafterstroke.com/book or join the Patreon at patreon.com/recoveryafterstroke All right, back to the episode. Vincent Thijs (11:51) All right, so we recruited from a variety of sources. So we had kept a log of people that were interested in this. We had a Facebook post in New Zealand, for instance, where we recruited as well. We had people from the Stroke Clinical Registry that were approached. We had a website and people could register their interest if they were doing a search online to participate in clinical trial. So the variety of sources and then we have to determine eligibility that was mostly done either via an in-person visit or remotely via telehealth. We tried to get their medical information, what type of stroke they had. And then we also questioned whether they had this modified rank in scale, the disability they had, the impairments they had from their stroke. so then people came. they were considered eligible, then we scheduled a visit and they would typically come in no overnight stay needed. It was a day procedure that was done. People were then receiving another questionnaire on the day itself to measure their quality of life and other measures like their fatigue levels and how much help they required, etc. And then we proceeded with the injection, which was done. We had bought a special bed that was able to do the, the, the tilting that was required. So we set the people up, injected and then tilted the table. so, we received the drug. It was prepared independently by the pharmacist. So the pharmacist, they took the drug off the shelf or the made the placebo. and they made sure it looked exactly alike. So then somebody from the trial team picked it up from the pharmacist. The pharmacist didn’t tell, of course, what it was. And then the administration happened. So the doctor who administered and the participant did not know what they received. So after the procedure, they were left like this for four minutes. And then after four minutes, people could sit up again. And we waited about half an hour. then we asked them how they were doing, whether there were any adverse reactions, ⁓ and ⁓ then after that half an hour of observation people could go back to their habitual situation. ⁓ it’s a very simple ⁓ procedure to do. Bill Gasiamis (14:35) I believe there was a was there 126 participants Vincent Thijs (14:40) Yes, 126 people participated. had anticipated a little bit more people to participate. So we had hoped 168, but recruitment fell flat after a while and we were not able to find more people to recruit. So we made a decision and then, you know, these clinical trials, they have some funding ⁓ and they require the treatment team to be paid, et cetera, and that ran out. So we had to stop at a certain time. Bill Gasiamis (15:13) Was the study stopped early because of a decrease in the amount of funding or was there an issue with the funding at some point? Vincent Thijs (15:23) Funding ran out. You hire people for a certain amount of years and then you have fewer patients than you anticipate. So you have to stop. Bill Gasiamis (15:32) huh, okay. So would that affect the outcome of the trial? Would you say the lack of funding or the lack of the ability to take the trial further? Vincent Thijs (15:42) Yeah, well, what we had when you do the trial, when you plan the trial, you say, well, this is what we’re going to expect in terms of efficacy. You have to make a guess and say, well, that many people will have an improvement in quality of life if we give them the placebo and that many people will have an improvement in quality of life with the trial drug. And we had thought that about 11 % would improve with the placebo based on an earlier study. And then we had to make a guess because nobody had done this type of study on what Etanosap would provide. But reading the report that was published several years ago now, where 90 % of the people reported improvement in their impairments, we thought, well, Let’s not go for 90%, but a 30 % improvement. And so that was based on that we needed 168 people to participate in the trial. So that was what we call the pre-planned sample size estimation, which is a guess. When we stopped at 126 participants, actually we saw that the results were very different. There was not that 11 % actually in the placebo arm. saw that 58 % of the people also had that improvement and 53 % had it with ethanosab. So our initial guess was very wrong based on some statistical advanced statistical techniques we have. We have quite a lot of power to estimate whether there was a difference. So I think the trial can provide us an answer. It’s large enough to give us an answer about this particular question. Is current clinical practice in these people with this range after their stroke, does it improve? quality of life after a month or after two months. I’m not speaking about early improvement, I’m not speaking about six months down the line. We only can decide what we see in this study. Bill Gasiamis (18:05) So you have some limitations because you can’t have the funding to test one month, two months, six months, 12 months. You have the funding to basically meet the design of your study and then you can report on that. Now what’s really interesting is that the placebo had such a large result. PESTO Trial Results and Findings Vincent Thijs (18:34) What kind of things were people reporting that improved for the people who had the placebo injection?Look, this is, course, when we were in the blinded phase, when neither myself or my colleagues who did these scales, we were totally blinded. And that’s, remember vividly people saying, it didn’t do anything for me. But then there were also people said that they could see again. And so people that had improvement in sensation. Some people had improvement in their speech. there were, we, we observed these things, but we didn’t know whether they were active or placebo. And then surprisingly we had some people in whom we thought, they must have had active drug that turned out to have the placebo, but that’s years after, right? Because it takes a little bit of time to accumulate a sufficient number of patients. And we were only reporting and breaking the blind when the trial was finished. because otherwise you may be biased in all your analysis, et cetera. You don’t want to do that. So you wait until the end of the study to break the blind. And that’s very frustrating for the participants because there were many people that said, I must have had the placebo because it didn’t do anything for me. And there were other people that were, and some people like that, they said, I still want to go to the US. Bill Gasiamis (19:37) I see. Vincent Thijs (19:59) And please, can you tell me if I received a placebo? And I understand it was terribly frustrating for these participants. But we were very strict. No, we don’t want to break the blind. This is against the rules that you have to adhere to in a clinical trial. And so we didn’t do that. Of course, once the trial was finished, we were able to report the results back to the the participants. And then there were some people that were very surprised that they had received the active drug. I remember one person vividly who said, you have to tell me now because I’m going. And then I said, hold off, hold off. And then we told them you had twice the active drug. And so they decided not to go anymore. So you see how From a clinical trial perspective, it’s very important to remain very objective and not being able to see what people have received. From a humane level, of course, I understand it was very important to these people. Bill Gasiamis (21:02) Yeah, that’d be difficult. ⁓ And then I imagine that had the placebo not worked and then the tenisept did work, then there would have been people who would have said, well, I’ve received the placebo. It didn’t work for me. Other people received the tenisept. It did work for them. Why can’t I get the tenisept injection now? Vincent Thijs (21:26) Yeah, and we also had two people, people that had twice the placebo who noticed an improvement and have told me the improvement is still there. Bill Gasiamis (21:35) Wow. Vincent Thijs (21:36) So it. Bill Gasiamis (21:38) That’s amazing. Now was the. Vincent Thijs (21:40) And often that, and I must tell you, often those were relatively little things that seemed to improve both with the placebo and in the active group. And you see that there are changes in quality of life that people have reported, but it happens as well with the placebo. Bill Gasiamis (21:58) Wow. Was the intention of the study that was funded at the very beginning in 2016 by Minister Hunt, was it to determine whether or not this was going to be an effective treatment for people in stroke and therefore to roll it out somehow in the Australian medical system for stroke survivors? What was the thinking for Minister Hunt? Do you know? Vincent Thijs (22:24) Of course, I was not involved in that lobbying to the minister or anything, but it was to bring it on a pathway towards regulatory approval. We know that Etanercept is a relatively cheap drug that you can get ⁓ and is approved already for some indications, especially in people with rheumatoid arthritis, the condition of the joints, but it’s not approved for stroke. And to be officially approved and then potentially re- reimbursed on the PBS. You need to have some trials that have been done such as PESTO. We do different trial phases. One would be a phase two trial and a phase three trial. So phase one is typically in people just to assess the safety and some dosages usually in healthy people. And then a phase two is safety amongst stroke survivors. and preliminary efficacy. And that’s where PESTO was what we call a phase two B trial. And then a phase three trial would then be a trial in many more participants based usually on the results of a phase two B trial. And then usually when you have a phase three trial and it’s convincing and the authorities may approve such a trial. Bill Gasiamis (23:46) So in this case, the phase two B trial, this PESTO trial didn’t find that it’s efficacious. And as a result, there’s not going to be a further trial. Would that be accurate? Vincent Thijs (23:56) Well, based on the findings we have in this particular type of ⁓ way of administering in this particular group of people, I don’t think there’s enough evidence to argue for a phase three trial. It may be that you could say, well, we want to focus on pain because that was more promising. Well, you’ll need to do another trial in that condition. Implications and Future Directions for Research After stroke or maybe within a year after stroke. I mean, there are other possibilities, but at the moment, current clinical practice type trials, I don’t think there’s enough evidence to move forward with that. Bill Gasiamis (24:43) What would the numbers have had to look like for the trial to conclude that there was evidence of efficacy? Vincent Thijs (24:51) Well, I think based on what we have now, you would need to design a much, much bigger trial because there was only a 5 % difference between the placebo and the active group. And actually it was in favor of the placebo. So the placebo did a little bit better, not statistically significant. So it could just be by chance, but you would need probably thousands of people. Bill Gasiamis (25:15) I see. And I imagine there’s not a lot of excitement about funding something like that by the people who fund these trials. Vincent Thijs (25:25) Yes, typically the funders will look at how good is the evidence to pursue this. And if you were a pharmaceutical company on a pathway to development for a drug, you probably would say, well, it looks safe, but it didn’t do what it intended to do. So let’s stop the development of this drug for this indication. Bill Gasiamis (25:45) I say so. I think one of the challenges with the path of administering a TANACEP to stroke survivors is that there seems to be a missing step. And the step to me is determining whether or not somebody is a candidate for a TANACEP. perhaps if we knew more about the stroke survivor, what was actually happening in their particular brain, and we were able to determine some similarities between the people who have had a positive result and we developed a method, then that would make it a lot easier. to say, well, I’m a stroke survivor. I’d like to have a TANACYPT and then go through a process of determining whether or not I was a candidate rather than just guessing whether I’m a candidate or not and then having to pay money to find out whether in fact I was a candidate. Vincent Thijs (26:33) The trial provides a little bit of answers to that. ⁓ You want to identify a marker or a subgroup of people in whom the drug will work particularly well. And so you could look at, and we looked at different things like females versus males, if you’re younger versus older, if you have very severe disability or less severe disability, if you have diabetes, are you early after your stroke or later? That one to five versus six to 15 category. And we could not identify a group in whom the the drug worked particularly well. Now there’s a caveat when you do a clinical trial, it’s really hard to look at subgroups, especially if your trial is relatively small and the PESTO trial is relatively small. So you have to take this with a grain of salt, but it was nothing really promising. that we could identify. So probably you need other markers. If you believe in Etanercept as a drug, you would possibly need to look at what are the levels of TNF alpha, the drug, the molecule that actually is targeted. Unfortunately, there’s nothing like readily available to do that. Could it be that people with a… a stroke in a particular location that would work particularly more than in others, but we don’t have any real way at the moment to do that. Bill Gasiamis (28:08) Okay, so we’re assuming that the people who experience an improvement after they’ve had an attempt to shut that the markers of TNF alpha were lower or higher or Vincent Thijs (28:21) Well, the theory is that they have a lot higher TNF-alpha. Now, as you know, the premise is Etanercept works by reducing this molecule and we have good evidence that it reduces this molecule in the blood, but we don’t have good evidence that it reduces the levels in the brain. That’s where you want it to be. And one of the difficulties and many scientists that work on the Etanercept and ⁓ have said, look, it doesn’t cross the blood-brain barrier. It doesn’t. go against the natural defense that we have to protect the brain against substances that could potentially be harmful for the brain or that have a large size. And the Tandacep we know has a large size would not cross the blood-brain barrier. So it doesn’t reach the brain. And many people look at it with relative skepticism that it actually enters the brain. Bill Gasiamis (29:18) ⁓ And then with regards to rheumatoid arthritis, doesn’t need to cross the blood-brain barrier. It just somehow gets to this, position or the place where inflammation is occurring. TNF-alpha is active and it can easily mitigate the impact that TNF-alpha is causing. In the brain, the brain is protected by the blood-brain barrier and it cannot cross the blood-brain barrier under normal conditions and therefore it can’t get to where the TNF-alpha is. if there’s any TNF alpha, if inflammation is the issue and it cannot resolve it one way or another. So for some people perhaps it can’t resolve it. Now, I don’t understand about Etanercept a lot. I don’t understand exactly how the molecule works, et cetera. But if it was injected into a blood vessel, is that not something that can occur? And if it was, if it can occur, would that then cross the blood brain barrier? Vincent Thijs (30:15) That wouldn’t cause a blood brain barrier, no. You would have to do what we call a lumbar puncture or put a little ⁓ injection into the ventricles and then hope that it would enter the area that is stark where the TNF alpha is elevated. Those experiments have not been done. Bill Gasiamis (30:17) Either. Okay, so a lumbar puncture is probably riskier than… Vincent Thijs (30:44) Well, it’s uncomfortable. It’s uncomfortable and we do it to administer drugs if needed. Some people with brain cancer receive it. There are other trials ongoing in certain areas of stroke where it’s done. Bill Gasiamis (30:58) Then the difficulty is, and my job here is to report back to the community how they should proceed with Etanercept going forward. Now, I don’t expect you to answer that. However, your study probably gives enough information for people to be able to make an even more informed decision than they did before. Previously, what I think was happening is people, and it still happens every day. And I’ve interviewed a lot of stroke survivors who’ve had positive results with Etanercept. The challenge is getting interviews with stroke survivors who have had negative results with Etanercept. That is something I haven’t been able to do. So if somebody happens to be watching and listening to this and they have had the Etanercept shots and they didn’t get positive results, please reach out so that we can share a balanced story of what’s happening out there in the community. Would there be a reason for the community to perhaps begin again to lobby a government or a minister of a government to look at perisponinal tenosept and study it in a different way, like administration via a lumbar puncture. Conclusions and Final Thoughts Vincent Thijs (32:08) I think we need more, probably go back to the drawing table to see whether, because we’re just taking a step back. The idea is that there is inflammation after stroke and we know that there is inflammation after stroke. We don’t, we just don’t know how long it is. We don’t have a good marker. Is it present only for weeks or months after stroke or can it persist for years? The theory is that it persists for years, but if you look at the actual experiments that have been done, it’s really hard to study in humans because we don’t have good tests. But if you look in animals, it’s also hard to do long-term studies in animals, but nobody has really proven that conclusively that there is still after the stroke causes a scar, that process is still really active. Is TNF-alpha years after a stroke still present? Yes, it’s present because we use TNF as a transmitter in the brain or a chemical in the brain, but is it still worth reducing its activity? That’s probably, I think, a bigger question that science needs to answer is to understand that all inflammation piece and the time after stroke that it persists in my Bill Gasiamis (33:35) Yeah, because it could still be the fact that the person has had brain damage. The particular part of their brain that’s damaged has, for example, taken offline one of their limbs and there is no way to recover that once it’s gone. there is no, there may also be no inflammation ⁓ there. So somebody in that situation receiving Etanercept wouldn’t get a result even if it was able to cross the blood-brain barrier because the damage is done and that’s the challenge with the brain is once it’s damaged restoring the damaged part is not possible. Vincent Thijs (34:15) Yeah, look, after this experience with the PESTA trial, I think we need to work on other avenues and I’m not as hopeful with this based on the data that I have seen. Bill Gasiamis (34:28) Yeah Well, my final question then is, are you planning on exploring inflammation and recovery after stroke with any work that you’re doing in the future? Is there any more of this type of work being done? Vincent Thijs (34:46) we’ve just launched a new study, which is not a randomized trial, but it’s trying to get at this common symptom that people have after stroke, which is fatigue and cognitive changes. And one of my post-docs, Dr. Emily Ramech, she’s a physio by background. We just launched what we call the deep phenotyping study after stroke. And we are looking at young people that have had a stroke up to age 55 and we’re taking them into the scanner. We will do a PET scan that’s looking at inflammation. We’re taking their bloods and looking at markers of inflammation and see how that relates to fatigue after stroke. This is between the first month and the sixth month after stroke. That will give us a little bit of timeline of inflammation after stroke. It will give us some information about fatigue, which is very common, but I have no plans at the moment to look at ethanocephaly. Bill Gasiamis (35:53) Fair enough. I appreciate your time. Thank you so much. All right, well, that brings us back to the end of the episode with Professor Vincent Dease on the PESLO trial results. My hope is that this conversation gives you more clarity, especially if you’re felt caught between personal stories, strong opinions, and a lot of uncertainty. The goal here isn’t to tell you what to do. It’s to help you ask better questions and make decisions with your eyes open alongside a qualified healthcare professional who knows your situation. If this episode helped you, please do a couple of things. Subscribe on YouTube or follow the podcast on Spotify or Apple. Leave a review if you can. It really helps more stroke survivors find the show. And if you’ve had an experience you’re willing to share respectfully, positive, negative or mixed, add a comment. Those real-world perspectives help community feel less alone. And if you’d like to support the podcast and keep it going, my book is at recoveryafterstroke.com/book. And you can join the Patreon at patreon.com/recoveryafterstroke. Thanks for being here with me. And remember you’re not alone in this recovery journey. Importantly, we present many podcasts designed to give you an insight and understanding into the experiences of other individuals. Opinions and treatment protocols discussed during any podcast are the individual’s own experience, and we do not necessarily share the same opinion, nor do we recommend any treatment protocol discussed. All content on this website and any linked blog, podcast or video material controlled this website or content is created and produced for informational purposes only and is largely based on the personal experience of Bill Gassiamus. Content is intended to complement your medical treatment and support healing. It is not intended to be a substitute for professional medical advice and should not be relied on as health advice. The information is general and may not be suitable for your personal injuries, circumstances or health objectives. Do not use our content as a standalone resource to diagnose, treat, cure or prevent any disease for therapeutic purposes or as a substitute for the advice of a health professional. Never delay seeking advice or disregard the advice of a medical professional, your doctor or your rehabilitator. program based on our content. you have any questions or concerns about your health or medical condition, please seek guidance from a doctor or other medical professional. If you are experiencing a health emergency or think you might be, call 000 if in Australia or your local emergency number immediately for emergency assistance or go to the nearest hospital emergency department. Medical information changes constantly. While we aim to provide current quality information in our content, we do not provide any guarantees and assume no legal liability or responsibility for the accuracy, currency or completeness of the content. If you choose to rely on any information within our content, you do so solely at your own risk. We are careful with links we provide. However, third-party links from our website are followed at your own risk and we are not responsible for any information you find there. The post PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs appeared first on Recovery After Stroke.

In this episode, Chris and Graeme discuss the latest FC26 updates, focusing on the Unbreakable promo, gameplay experiences, and player recommendations. They analyze various icons and heroes, share insights on SBC's, and explore objectives within the game. The conversation highlights the importance of player roles and playstyles, providing listeners with valuable tips for enhancing their FC experience.Chapters00:00 Welcome and Introduction02:05 FC26 Gameplay and Weekly Updates05:14 Unbreakable Promo Details12:22 Icon and Hero Player Analysis20:54 Main Team Player Insights27:56 SBCs and Player Recommendations36:14 Objectives and Future PlansCheck out our socials:X: https://twitter.com/futinreviewBlueSky: https://bsky.app/profile/futinreview.bsky.socialInstagram: https://instragram.com/futinreviewTolando's socials:https://x.com/Tolando77https://www.instagram.com/tolando77/?hl=enhttps://www.tiktok.com/@tolando77https://www.youtube.com/@Tolando77https://www.twitch.tv/tolando77Questions:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠futinreview@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/futinreview⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.futinreview.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/futinreview⁠

Vitamin B12 is essential for energy production, nervous system function, and overall metabolic health, but not all B12 forms deliver equal bioavailability or stability. In Episode #196 of the PricePlow Podcast, we welcome back HTBA (HealthTech BioActives) for a comprehensive deep dive into the science behind their MecobalActive methylcobalamin ingredient and the groundbreaking clinical study that validates its efficacy in athletes who are not deficient. Joining us are Teresa Pellicer, PhD, Pharmacologist and R&D Manager in Biotechnology at HTBA, and Bernardo Gonzaga, Global Division Manager for Functional Health Solutions. This conversation builds on Episode #188 with Edwin Gonzalez, where we explored practical applications of MecobalActive in functional foods. Today, we go deeper into the molecular mechanisms, clinical evidence, bioavailability data, and manufacturing innovations that make MecobalActive a next-generation B12 solution for supplements, functional foods, and beverages. Teresa’s expertise in pharmacology and molecular biology shines as she explains why methylcobalamin represents the biologically active form your body actually uses, while Bernardo provides industry context on applications, regulatory considerations, and market opportunities. Subscribe to the PricePlow Podcast on your favorite platform, and sign up for HTBA news alerts before we dive into the science. https://blog.priceplow.com/podcast/podcast/htba-mecobalactive-vitamin-b12-196 Video: The Science Behind MecobalActive Vitamin B12 https://www.youtube.com/watch?v=3v5NgW5jD-E Detailed Show Notes: Teresa Pellicer and Bernardo Gonzaga Discuss MecobalActive B12 (0:00) – Welcome and Introductions (2:00) – Teresa’s Background in Pharmacology and Molecular Biology (4:15) – Bernardo’s Industry Journey and Global Perspective (6:30) – HTBA Company History and Four Business Divisions (9:15) – Pharmaceutical-Grade Quality for Injectable B12 (11:00) – Sustainability Story: Upcycling Baby Oranges for Bioflavonoids (13:45) – ESG Commitment Beyond Environmental Impact (16:00) – Why Vitamin B12 Matters for Energy and Health (19:30) – The Four Main Forms of Vitamin B12 (22:45) – Why Cyanocobalamin Dominates Despite Conversion Requirements (26:15) – MecobalActive: Solving Methylcobalamin’s Stability Challenge (29:45) – The Clinical Study Design and Objectives (33:00) – Study Results: Superior Bioavailability and Faster Absorption (36:30) – Methylation Pathways and Homocysteine Metabolism (40:00) – Adenosylcobalamin and Mitochondrial Energy Production (43:45) – Populations at Risk for B12 Deficiency (47:15) – Symptoms and Consequences of B12 Deficiency (51:00) – Absorption Mechanisms: Intrinsic Factor Pathway (54:45) – Passive Diffusion and High-Dose Supplementation (58:15) – Manufacturing Challenges with Methylcobalamin Stability (1:01:30) – Applications in Functional Foods and Beverages (1:05:00) – Dosing Considerations and Safety Profile (1:08:30) – Combining B12 with Other B Vitamins and Nutrients (1:12:00) – Regulatory Landscape Across Global Markets (1:15:45) –… Read more on the PricePlow Blog

Send us a textMr. Gene Warr was a successful businessman in Oklahoma, who developed the real estate subdivision Warr Acres in NW Oklahoma City, among other ventures. He and his wife Irma made a tremendous impact on numerous people during their lifetimes. He was instrumental in starting the Baptist Student Union. He was a direct influence on Jim Morris, the founder of the Kansas Communities Ministry. This message is from a talk he gave to a conference to the Kansas Communities Ministry in 1988. Richard Spann's blog Starting Where You Are detailing the connection with the Kansas Navigators. 

In this episode, Chris, Graeme and Neil discuss the latest FC updates, focusing on the Joga Bonito promo, player recommendations, and surprising performances. They share their experiences in FC26, highlight new heroes, and explore objectives and fun cards. The conversation wraps up with reflections on players that have exceeded expectations and the overall state of the game.TakeawaysThe Joga Bonito promo emphasizes flair and skill in gameplay.Players are finding the current FC content overpriced and less enjoyable.New tactics and formations can enhance the gaming experience.Certain players, like Alicia Thompson, are surprisingly effective despite their stats.The importance of play styles in player performance is highlighted.Heroes like Pablo Aymar and Cesc Fabregas bring nostalgia and excitement.Objectives in FIFA can be a fun way to engage with the game.Surprising player performances can keep players invested in FIFA.The community aspect of FC26, including Discord interactions, is valuable.The hosts express a mix of excitement and disappointment about the current state of FC26. Chapters00:00 Introduction to Joga Bonito and FC Gameplay03:05 Exploring the Joga Bonito Promo06:11 Player Highlights and Market Insights08:55 Evaluating New Heroes in FC11:55 Discussion on Evolution Cards and Their Value14:59 Fun Cards and Player Recommendations20:12 Chemistry and Player Evaluation23:02 Objectives and Gameplay Experience26:18 Promo Insights and Future Expectations27:49 Surprising Player Performances35:07 Gold Players Still in the GameCheck out our socials:X: https://twitter.com/futinreviewBlueSky: https://bsky.app/profile/futinreview.bsky.socialInstagram: https://instragram.com/futinreviewTolando's socials:https://x.com/Tolando77https://www.instagram.com/tolando77/?hl=enhttps://www.tiktok.com/@tolando77https://www.youtube.com/@Tolando77https://www.twitch.tv/tolando77Questions:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠futinreview@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/futinreview⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.futinreview.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/futinreview⁠

PREVIEW — Brandon Weichert — Trump Administration Prioritizes Business Deals Over Military Strategy. Weichert predicts the incoming Trump administration will prioritize commercial business transactions and corporate profit objectives over rigorous military and geopolitical strategy, potentially authorizing high-end semiconductor chip sales to China despite critical American technological military advantage implications. Weichert warns that this approach, unchecked by a "compromised" Congress lacking geopolitical sophistication, suggests the administration may deliberately abandon strategic commitment to the "first island chain" (Japan, Taiwan, Philippines) to secure access to critical minerals and agricultural soybeans from Chinese-influenced suppliers. Weichert characterizes this as a fundamental erosion of American military dominance and regional security architecture in the Indo-Pacific.

Paul Hoynes and Joe Noga look at what the Guardians can do to bolster their lineup at the MLB winter meetings. Learn more about your ad choices. Visit megaphone.fm/adchoices

Peace Envoys and Russian Consistency — Gregory Copley — Copley analyzes the Trump administration's envoys visiting Moscow, contrasting Russia's remarkably consistent long-term strategic objectives with perceived Americaninconsistency and shifting priorities. Copley predicts that U.S.-Russia negotiations will result in substantial territorial concessions to Russia, generating alarm among European allies regarding American commitment to regional security. Copley highlights President Putin's upcoming state visit to India as strategically critical for establishing Russia's post-China global positioning and diversifying geopolitical relationships independent of Western European and Americanengagement frameworks. 1914 RUSSIA ARTILLERY

State Department Strategy and Moscow — Mary Kissel — Kissel explains that State Department strategic objectives prioritize implementing President Trump's directive to remove Maduro from Venezuelan power while ensuring American national security and hemispheric stability. Kissel details that Trump envoys currently in Moscow encounter Putin's two-track negotiating strategy: offering economic incentives for Russian reintegration into global markets while simultaneously demanding substantial Ukrainian territorial concessions and NATO exclusion from Eastern Europe. Kissel emphasizes the strategic complexity of reconciling U.S. interests in Ukrainian sovereignty with Russian security demands regarding sphere of influence and buffer state arrangements. 1961 BERLIN

2/4. Naming OSIRIS-REx and Overcoming Major Hurdles — Dante Lauretta — Following successive rejections, Lauretta systematically defined the mission's core scientific objectives—Origins, Spectral Interpretation, Resource Identification, Security—establishing the OSIRIS framework and subsequently designating the mission OSIRIS-REx(Regolith Explorer). The mission received formal selection in 2011, and Mike Drake, serving as Lauretta's mentor while managing significant personal health challenges, designated Lauretta as "risk mitigation" leader. The team confronted and resolved critical technical obstacles, particularly the guidance system architecture, during the rigorous 2014 NASA review process, successfully enabling the planned 2016 launch. 1955

Montgomery, commanding ground forces for D-Day, gave a "scintillating" and persuasive briefing on his revised Overlord plan. He set objectives in Normandy, like capturing Caen, that were perhaps beyond the means of his exhausted British troops, worsening his relationship with American generals. Montgomery's Operation Market Garden failed to achieve its objectives; the absence of his trusted chief of staff, Freddy Duingan, removed a critical checks and balances system. Rommel showed moral courage by standing up to Hitler in June 1944, arguing the war was over and negotiations were necessary. Patton's swift repositioning of his Third Army to relieve Bastogne during the Battle of the Bulge was his finest hour, surprising both allies and Germans.

In this episode of the Second in Command Podcast, guest host Sivana Brewer sits down with Matthew Rathje, Chief Operating Officer of TrueNorth Companies and long-time member of the COO Alliance.From starting in payroll and claims management to leading operations for a $165M insurance and professional services firm, Matt shares his journey of scaling from the ground up, balancing structure, culture, and human leadership. He offers practical insights on bringing clarity and accountability to fast-growing organizations, structuring meetings that actually move the needle, and building trust without falling into “artificial harmony.”Matt also opens up about navigating personal and professional adversity, from weathering the 2020 derecho storm that destroyed his family's home, to leading through COVID-19, and how those experiences shaped his leadership philosophy rooted in humility, collaboration, and optimism.Timestamped Highlights[00:01:20] – Matt's journey at TrueNorth and how he helped the company grow from a local firm to a $165M organization.[00:05:16] – Lessons from moving between individual contributor and leadership roles.[00:07:00] – How TrueNorth's leadership transition inspired a more unified executive vision.[00:09:20] – Preparing to step into the COO role and finding mentors in the process.[00:10:44] – Why Matt joined the COO Alliance and what he learned from peers in other industries.[00:13:00] – Building clarity and accountability through RIMs and RIOs (Relatable Impact Metrics & Objectives).[00:15:00] – Starting TrueNorth's organizational health journey with Patrick Lencioni's Table Group.[00:17:34] – How Lencioni's framework helped the team prioritize what's most important right now.[00:18:46] – Team effectiveness workshops and how vulnerability-based trust builds healthy organizations.[00:20:35] – How to identify “artificial harmony” and address it before it erodes team commitment.[00:24:32] – Balancing collaboration with decisive leadership.[00:26:03] – Structuring meetings for clarity, speed, and results.[00:29:40] – How personal adversity (a devastating storm) strengthened Matt's leadership perspective.[00:33:54] – Leading with empathy, gratitude, and perspective through crisis.[00:38:52] – Building trust and vulnerability across teams.[00:40:31] – Strengthening the CEO-COO relationship and defining complementary strengths.[00:42:42] – Using Vivid Vision to align the entire company around purpose and feeling.[00:46:14] – Launching The TrueNorth Way: the company's roadmap for a world-class client experience.Resources & MentionsThe Apple Experience by Carmine GalloUnreasonable Hospitality by Will GuidaraMeetings Suck by Cameron HeroldThe Five Dysfunctions of a Team by Patrick Lencioni (and the related Five Behaviors of a Cohesive Team framework)About the GuestMatthew Rathje is the Chief Operating Officer of TrueNorth Companies, a Midwest-based insurance and professional services firm dedicated to protecting and maximizing its clients' assets, resources, and opportunities.Since joining TrueNorth over a decade ago,...